Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse

INTRODUCTION: 25% of Stage III colon cancer patients relapse within 5 years due to minimal residual disease (MRD) not eliminated by surgery and chemotherapy. We hypothesise that sub-types of MRD, defined by circulating tumour cells (CTCs) and bone marrow micro-metastasis (mM) have different types an...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ecancermedicalscience
Main Authors: Murray, Nigel P, Aedo, Sócrates, Villalon, Ricardo, López, Marco Antonio, Minzer, Simona, Muñoz, Lorena, Orrego, Shenda, Contreras, Luis, Arzeno, Lucas, Guzman, Eghon
Formato: Artigo
Idioma:Inglês
Publicado em: Cancer Intelligence 2019
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6605629/
https://ncbi.nlm.nih.gov/pubmed/31281432
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3332/ecancer.2019.935
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados